Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
EBA-175 RII-NG malaria vaccine
- Development stage
- Unknown
- Lead developer
- National Institute of Allergy and Infectious Diseases
- Modality
- Recombinant Proteins and Enzymes, Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
EBA-175 RII-NG is a recombinant protein subunit malaria vaccine developed by the National Institute of Allergy and Infectious Diseases (NIAID). The vaccine is based on the non-glycosylated Region II of the erythrocyte-binding antigen 175 (EBA-175), which is a conserved parasite ligand that mediates the invasion of human erythrocytes by binding to glycophorin A. Formulated with an aluminum phosphate adjuvant (Adju-Phos), the vaccine is designed to elicit antibodies that block this interaction, thereby inhibiting parasite growth. It has been evaluated in Phase I clinical trials in both malaria-endemic and non-endemic populations, demonstrating safety and immunogenicity.
- Other names
- EBA-175 RII-NG/Adju-PhosEBA-175 RII-NG vaccineEBA175 RII-NG vaccineEBA 175 RII-NG vaccine
02
Targets
EBP1 (Proliferation-associated protein 2G4)
Beyond the preview
Go deeper on EBA-175 RII-NG malaria vaccine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on EBA-175 RII-NG malaria vaccine.